Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 317,623Xls
2D Structure
Also known as: 1903008-80-9, Yh-25448, Gns-1480, Yh25448, Gns1480, Jnj-73841937-aaa
Molecular Formula
C30H34N8O3
Molecular Weight
554.6  g/mol
InChI Key
RRMJMHOQSALEJJ-UHFFFAOYSA-N
FDA UNII
4A2Y23XK11

Lazertinib is an orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, including the resistance mutation T790M, exon 19 deletions (Del19), and the L858R mutation, with potential antineoplastic activity. Upon administration, lazertinib specifically and irreversibly binds to and inhibits selective EGFR mutants, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Lazertinib may inhibit programmed cell death-1 ligand 1 (PD-L1) and inflammatory cytokines in specific cancer cells harboring certain EGFR mutations. Compared to some other EGFR inhibitors, lazertinib may have therapeutic benefits in tumors with T790M- or L858R-mediated drug resistance. In addition, lazertinib penetrates the blood-brain barrier (BBB). This agent shows minimal activity against wild-type EGFR (wtEGFR), and does not cause dose-limiting toxicities, which occur during the use of non-selective EGFR inhibitors and inhibit wtEGFR. EGFR, a receptor tyrosine kinase (RTK) mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide
2.1.2 InChI
InChI=1S/C30H34N8O3/c1-5-28(39)32-23-17-24(26(40-4)18-25(23)37-13-15-41-16-14-37)33-30-31-12-11-27(34-30)38-20-22(19-36(2)3)29(35-38)21-9-7-6-8-10-21/h5-12,17-18,20H,1,13-16,19H2,2-4H3,(H,32,39)(H,31,33,34)
2.1.3 InChI Key
RRMJMHOQSALEJJ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN(C)CC1=CN(N=C1C2=CC=CC=C2)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N5CCOCC5)OC
2.2 Other Identifiers
2.2.1 UNII
4A2Y23XK11
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2-propenamide, N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)-

2. Leclaza

3. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)acrylamide

2.3.2 Depositor-Supplied Synonyms

1. 1903008-80-9

2. Yh-25448

3. Gns-1480

4. Yh25448

5. Gns1480

6. Jnj-73841937-aaa

7. Lazertinib [usan]

8. C-18112003-g

9. N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide

10. 4a2y23xk11

11. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamide

12. 2-propenamide, N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)-

13. Leclaza

14. Lazertinib [inn]

15. Lazertinib [inn]

16. Lazertinib (yh25448)

17. Lazertinib [who-dd]

18. Unii-4a2y23xk11

19. Chembl4558324

20. Schembl17670400

21. Gtpl10136

22. Bcp30440

23. Ex-a1912

24. Bdbm50555575

25. S8724

26. Who 10587

27. Akos037515597

28. Ccg-270023

29. Lazertinib (yh25448,gns-1480)

30. Yh-25448;gns-1480

31. Ac-36243

32. Bs-15742

33. Compound 73 [wo2016060443a2]

34. Hy-109061

35. Cs-0032992

36. A16827

37. A903188

38. Yh-25448; Yh 25448; Yh25448; Gns-1480; Gns 1480; Gns1480

39. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)acrylamide

40. N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide

2.4 Create Date
2016-08-06
3 Chemical and Physical Properties
Molecular Weight 554.6 g/mol
Molecular Formula C30H34N8O3
XLogP33.4
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count9
Rotatable Bond Count10
Exact Mass554.27538698 g/mol
Monoisotopic Mass554.27538698 g/mol
Topological Polar Surface Area110 Ų
Heavy Atom Count41
Formal Charge0
Complexity837
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)